

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use ~~as~~ many sheets as necessary)

3

of

5

COMPLETE IF KNOWN

10/520.566

January 7, 2005

D.J. MacNeil et al.

21141YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/KW/			WO 02/38551		F. HOFFMAN-LA ROCHE AG	05/16/2002
/KW/			WO 02/40008		WARNER-LAMBERT COMPANY	05/23/2002
/KW/			WO 02/49648		SCHERING CORPORATION	06/27/2002
/KW/			EP 0 920 864		PFIZER PRODUCTS INC.	06/09/1999
/KW/			WO 03/009845		SCHERING CORPORATION	02/06/2003
/KW/			WO 96/16542		SYNAPTIC PHARMACEUTICAL CORPORATION	06/06/1996
/KW/			WO 97/19682		SYNAPTIC PHARMACEUTICAL CORPORATION	06/05/1997
/KW/			WO 97/20820		NOVARTIS AG	06/12/1997
/KW/			WO 97/20821		NOVARTIS AG	06/12/1997
/KW/			WO 97/20822		NOVARTIS AG	06/12/1997

/Kevin Weddington/ (06/05/2007)

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

INFORMATION DISCLOSURE

(use as many sheets as necessary)

Application Number	10/520,566
---------------------------	-------------------

Filing Date	January 7, 2005
--------------------	------------------------

First Named Inventor	D.J. MacNeil et al.
-----------------------------	----------------------------

Group Art Unit

Examiner Name

Attorney Docket Number 21141YP

3

of

5

[illegible][illegible]

/Kevin Weddington/ (06/05/2007)

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc. 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/520,566
Filing Date	January 7, 2005
First Named Inventor	D.J. MacNeil et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21141YP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/KW/	AA	Parker et al., Eur. J. of Pharmacology, Vol. 440 (2002), pp. 173-187, "Neuropeptide Y receptors as targets for anti-obesity drug development ..."
/KW/	AB	Dax, Drugs of the Future (2002), Vol. 27(3), pp. 273-287, "Small-molecule neuropeptide Y Y5 antagonists"
/KW/	AC	Ford et al., JAMA (2002), Vol. 287, pp. 356-359, "Prevalence of the metabolic syndrome among US adults"
/KW/	AD	Gadde, et al., JAMA (2003), Vol. 289, pp. 1820-1825, "Zonisamide for weight loss in obese adults"
/KW/	AE	Rowland et al., Psychopharmacology (2001), Vol. 159, pp. 111-116, "Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats"
/KW/	AF	Boozer et al., Metabolism, Vol. 50 (2001), pp. 889-893, "Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats"
/KW/	AG	Matson et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., Vol. 278 (2000), pp. R882-R890, "Cholecystokinin and leptin act synergistically to reduce body weight"
/KW/	AH	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"
/KW/	AI	Davidson et al., JAMA (1999), Vol. 281, pp. 235-242, "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat"
/KW/	AJ	de Vos et al., J. Biol. Chem., Vol. 270 (1995), pp. 15958-15961, "Induction of <i>ob</i> gene expression by corticosteroids is accompanied by body weight loss and reduced food intake"
/KW/	AK	Flier et al., Cell (1998), Vol. 92, pp. 437-440, "Obesity and the hypothalamus: Novel peptides for new pathways"
/KW/	AL	Abu-Elheiga et al., Science (2001), Vol. 291, pp. 2613-2616, "Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2"
/KW/	AM	Smith et al., Nature Genetics, Vol. 25 (2000), pp. 87-90, "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat"
/KW/	AN	Cummings et al., Nature, Vol. 382 (1996), pp. 622-626, "Genetically lean mice result from targeted disruption of the RIIβ subunit of protein kinase A"
/KW/	AO	Wadden et al., Obesity Research, Vol. 8 (2000), pp. 431-437, "Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone ..."

Examiner Signature

/Kevin Weddington/ (06/05/2007)

Date Considered


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT



COMPLETE IF KNOWN

Application Number	10/520,566
Filing Date	January 7, 2005
First Named Inventor	D.J. MacNeil et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21141YP

5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/KW/	AP	Menozi et al., British J. of Nutrition, Vol. 84 (2000), pp. 515-520, "Resting metabolic rate, fat-free mass and catecholamine excretion during weight loss in female obese patients"
/KW/	AQ	Sorribas et al., J. Pharm. Pharmacol., Vol. 44 (1992), pp. 1030-1032, "Effects of nicarbazin on intestinal digestion and absorption of nutrients in the rabbit"
/KW/	AR	Badr et al., Toxicology, Vol. 34 (1985), pp. 333-340, "Potentiation of methotrexate-induced gastrointestinal toxicity by non-steroidal anti-inflammatory drugs (NSAIDs) and vincristine"
/KW/	AS	Stanley et al., Peptides, Vol. 13 (1992), pp. 581-587, "Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect"
/KW/	AT	Guy-Grand et al., The Lancet, Vol. 2 (1989), pp. 1142-1145, "International trial of long-term dexfenfluramine in obesity"
/KW/	AU	Sahu et al., Trends Endocrinol. Metab., Vol. 4 (1993), pp. 217-224, "Neuropeptidergic regulation of feeding behavior"
/KW/	AV	Wolf, Nutrition Reviews, Vol. 59, No. 2 (2001), pp. 56-57, "The uncoupling proteins UCP2 and UCP3 in skeletal muscle"
/KW/	AW	Bray et al., Obesity Res., Vol. 7, No. 2 (1999), pp. 189-198, "Sibutramine produces dose-related weight loss"
/KW/	AX	Douglas et al., Int'l J. of Obesity, Vol. 7 (1983), pp. 591-595, "Plasma phentermine levels, weight loss and side-effects"

Examiner Signature

/Kevin Weddington/ (06/05/2007)

Date Considered

(use as many sheets as necessary)

DISCLOSURE
OIPF APPLICANT
DEC 11 2006
BANK OF CANADA
TRADEMARK OFFICE
(necessary)

Sheet

1

of

2

10/520,566

January 7, 2005

D.J. MacNeil et al.

1614

Attorney Docket Number

21141YP

[illegible][illegible]

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006